109 related articles for article (PubMed ID: 8054279)
21. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
Foekens JA; van Putten WL; Portengen H; de Koning HY; Thirion B; Alexieva-Figusch J; Klijn JG
J Clin Oncol; 1993 May; 11(5):899-908. PubMed ID: 8487052
[TBL] [Abstract][Full Text] [Related]
22. Protein tyrosine kinase activity in 350 T1/T2, N0/N1 breast cancer. Preliminary results.
Bolla M; Rostaing-Puissant B; Bottari SP; Chedin M; Marron-Charriere J; Colonna M; Berland E; Chambaz E
Breast Cancer Res Treat; 1996; 39(3):327-34. PubMed ID: 8877013
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer.
Foekens JA; Ries C; Look MP; Gippner-Steppert C; Klijn JG; Jochum M
Cancer Res; 2003 Jan; 63(2):337-41. PubMed ID: 12543785
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
Knoop A; Andreasen PA; Andersen JA; Hansen S; Laenkholm AV; Simonsen AC; Andersen J; Overgaard J; Rose C
Br J Cancer; 1998 Mar; 77(6):932-40. PubMed ID: 9528837
[TBL] [Abstract][Full Text] [Related]
25. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.
Schmitt M; Thomssen C; Ulm K; Seiderer A; Harbeck N; Höfler H; Jänicke F; Graeff H
Br J Cancer; 1997; 76(3):306-11. PubMed ID: 9252196
[TBL] [Abstract][Full Text] [Related]
26. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
Riisbro R; Christensen IJ; Piironen T; Greenall M; Larsen B; Stephens RW; Han C; Høyer-Hansen G; Smith K; Brünner N; Harris AL
Clin Cancer Res; 2002 May; 8(5):1132-41. PubMed ID: 12006529
[TBL] [Abstract][Full Text] [Related]
28. [Plasminogen activator inhibitor 1 and prognosis in breast carcinoma].
Mayerhofer K; Stolzlechner J; Yildiz S; Haider K; Heinzl H; Jakesz R; Pecherstorfer M; Rosen H; Sevelda P; Zeillinger R; Speiser P
Geburtshilfe Frauenheilkd; 1996 Jan; 56(1):23-7. PubMed ID: 8852782
[TBL] [Abstract][Full Text] [Related]
29. Multiparametric prognostic evaluation of biological factors in primary breast cancer.
Spyratos F; Martin PM; Hacène K; Romain S; Andrieu C; Ferrero-Poüs M; Deytieux S; Le Doussal V; Tubiana-Hulin M; Brunet M
J Natl Cancer Inst; 1992 Aug; 84(16):1266-72. PubMed ID: 1640487
[TBL] [Abstract][Full Text] [Related]
30. [Prognostic value of thymidine kinase in cancer of the breast].
Romain S; Javre JL; Samperez S; Jouan P; Bressac C; Varette I; Brandone H; Martin PM
Bull Cancer; 1990; 77(10):973-83. PubMed ID: 2249017
[TBL] [Abstract][Full Text] [Related]
31. [Tyrosine-protein kinase activity in breast neoplasm. Comparison with activity obtained in benign diseases and in normal tissues].
Pierart J; Oñate E; Klaassen R; Cid L; Gutierrez S; Talbot E; Ross E; Zambrano C; Burmeister R; Puchi M
Rev Med Chil; 1995 Feb; 123(2):165-75. PubMed ID: 7569456
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
Grøndahl-Hansen J; Peters HA; van Putten WL; Look MP; Pappot H; Rønne E; Dano K; Klijn JG; Brünner N; Foekens JA
Clin Cancer Res; 1995 Oct; 1(10):1079-87. PubMed ID: 9815897
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.
de Witte JH; Sweep CG; Klijn JG; Grebenschikov N; Peters HA; Look MP; van Tienoven TH; Heuvel JJ; van Putten WL; Benraad TJ; Foekens JA
Br J Cancer; 1999 Mar; 79(7-8):1190-8. PubMed ID: 10098758
[TBL] [Abstract][Full Text] [Related]
34. Protein tyrosine kinase activity as a prognostic parameter in breast cancer, a pilot study.
Bolla M; Rostaing-Puissant BR; Chedin M; Souvignet C; Marron-Charriere J; Colonna M; Berland E; Chambaz EM
Breast Cancer Res Treat; 1993; 26(3):283-7. PubMed ID: 8251653
[TBL] [Abstract][Full Text] [Related]
35. The prognostic value of BCAR1 in patients with primary breast cancer.
Dorssers LC; Grebenchtchikov N; Brinkman A; Look MP; van Broekhoven SP; de Jong D; Peters HA; Portengen H; Meijer-van Gelder ME; Klijn JG; van Tienoven DT; Geurts-Moespot A; Span PN; Foekens JA; Sweep FC
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6194-202. PubMed ID: 15448007
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
Descotes F; Riche B; Saez S; De Laroche G; Datchary J; Roy P; André J; Bobin JY
Clin Breast Cancer; 2008 Apr; 8(2):168-77. PubMed ID: 18621614
[TBL] [Abstract][Full Text] [Related]
37. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
[TBL] [Abstract][Full Text] [Related]
38. The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival.
Pedersen AN; Christensen IJ; Stephens RW; Briand P; Mouridsen HT; Danø K; Brünner N
Cancer Res; 2000 Dec; 60(24):6927-34. PubMed ID: 11156392
[TBL] [Abstract][Full Text] [Related]
39. [The effects of genistein on tyrosine protein kinase-mitogen activated protein kinase signal transduction pathway in hypertrophic scar fibroblasts].
Cao C; Li SR; Dai X; Chen YQ; Feng Z; Qin X; Zhao Y; Wu J
Zhonghua Shao Shang Za Zhi; 2008 Apr; 24(2):118-21. PubMed ID: 18785412
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Borstnar S; Vrhovec I; Svetic B; Cufer T
Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
